MTL-004 / Gordian Pharma - LARVOL DELTA

MTL-004, a promising new therapeutic for post-resection treatment of glioblastoma (AACR 2025) - "Sequential collection of blood and organs were performed and radioactivity was measured.Efficacy of MTL-004 on tumor bearing rats:On day 0, tumors were orthotopically induced by implanting 9L fragments into the brain of Fischer 344 female and male rats.On day 5, developing tumors were surgically resected, and rats were subsequently treated with either temozolomide (TMZ), the current standard of care model, orally (PO) for 5 consecutive days, a single application of a bioresorbable paste containing MTL-004, or both treatments combined.Tolerance and biodistribution of MTL-004:Based on IV dosing, 5 mg/kg/day was considered to be the maximum tolerated dose of MTL-004. MTL-004 was found to be safe and well-tolerated at a dose of 1 mg/kg, and was excreted mainly through urine.Following resection, PO TMZ seemed to have a transient impact on tumor growth, but minimal survival gains compared to placebo. In contrast, a single IC treatment with MTL-004 in paste provided prolonged..."

Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Intra-cranial administration of MTL-004, a promising post-resection treatment for glioblastoma (AACR 2024) - "Comparison is made with oral temozolomide (TMZ), the current standard of care (SOC), following resection.Experimental procedures On day 0, 2 mm3 tumor fragments were implanted into the brains of healthy female and male Fischer rats.On day 5 rats the growing tumors were removed using microsurgery. Rats treated with MTL-004 had a significantly higher survival compared to both placebo and TMZ groups and remained in apparent good health for the 58 days of the study.Conclusions Consistent trends were observed in each group of male and female rats following tumor resection.•PGLA/PEG paste with MTL-004 or without (placebo) or were both well tolerated.•Treatment with MTL-004 in PGLA/PEG paste provided good tumor control, was better tolerated and led to significantly greater survival than oral TMZ or placebo.•Oral TMZ (SOC) provided control of tumor volume but was associated with significant, transient body weight losses and no significant survival gain compared to placebo.Our..."

Late-breaking abstract • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor